UK Fines Reckitt $16M For Thwarting Generic Meds

Law360, New York (October 15, 2010, 11:14 AM EDT) -- The U.K. Office of Fair Trading has fined Reckitt Benckiser Group PLC £10.2 million ($16.4 million) for withdrawing its National Health Service supply of Gaviscon heartburn medication in order to thwart access to generic alternatives.

The competition watchdog announced Friday that Reckitt Benckiser admitted to violating UK and European competition law in 2005 by pulling one Gaviscon product from the NHS prescription channel and delisting it, leading pharmacies to issue another Reckitt product rather than generic versions of the heartburn medicine.

Reckitt timed the withdrawal of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.